Lecithin / ROS Cancer Research Results

LEC, Lecithin: Click to Expand ⟱

Features:

Note Lecithin and Choline are related

Lecithin — a naturally occurring mixture of amphiphilic phospholipids, typically rich in phosphatidylcholine, used extensively as a food-grade emulsifier, solubilizing agent, phospholipid carrier, and bioavailability-enhancing excipient. Standard abbreviation: LEC. Commercial lecithin is commonly derived from soy, sunflower, or egg. Its most therapeutically relevant property is its ability to organize lipids and poorly water-soluble compounds into emulsions, nanoemulsions, liposomes, mixed micelles, and phospholipid complexes, thereby improving dispersion in aqueous environments, protecting susceptible compounds, facilitating gastrointestinal solubilization, and in selected formulations increasing oral absorption and systemic exposure.

Primary mechanisms (ranked):

Oil-in-water emulsification — lowers interfacial tension and stabilizes dispersed lipid droplets, allowing hydrophobic compounds to remain dispersed in aqueous environments.
Improved gastrointestinal bioaccessibility — increases the fraction of lipophilic compounds transferred into digestible lipid droplets and mixed micelles that can approach the intestinal epithelium.
Phospholipid complex formation — associates with poorly soluble molecules and can improve apparent aqueous dispersibility, membrane affinity, and gastrointestinal absorption.
Nanoemulsion and liposome formation — enables nanoscale carrier systems that increase surface area, protect encapsulated compounds, and modify intestinal release and absorption.
Protection from chemical degradation — encapsulation can reduce photochemical, thermal, oxidative, or aqueous degradation of susceptible lipophilic compounds.
Enhanced systemic exposure of co-formulated compounds — formulation-dependent increases in Cmax and AUC have been demonstrated for compounds including curcuminoids, quercetin, silybin, and carnosic acid.

Bioavailability / PK relevance: Lecithin can markedly improve the oral bioavailability of poorly water-soluble compounds when incorporated into optimized phospholipid complexes, oil-in-water emulsions, nanoemulsions, or related lipid delivery systems. Human pharmacokinetic studies have reported approximately 29-fold greater total curcuminoid absorption from a lecithin-based formulation and plasma quercetin exposure up to approximately 20-fold above unformulated quercetin. However, these effects are formulation-specific and should not be interpreted as evidence that simply consuming lecithin together with a compound will reproduce the same enhancement.

In-vitro vs systemic exposure relevance: In-vitro digestion models consistently show that lecithin-containing emulsions can increase apparent solubility, micellarization, and bioaccessibility of lipophilic compounds, but improved bioaccessibility does not necessarily translate proportionally into systemic bioavailability. Formulation parameters including lecithin concentration, carrier oil composition, droplet size, gastrointestinal stability, and competing emulsifiers strongly influence the outcome. Human or animal pharmacokinetic evidence is therefore preferred when assigning quantitative enhancement factors.

Clinical evidence status: Strong formulation and preclinical evidence; human pharmacokinetic evidence exists for several lecithin/phosphatidylcholine delivery systems. Lecithin itself is not an anticancer therapy, but it is a clinically relevant pharmaceutical and nutraceutical excipient capable of substantially modifying exposure to co-formulated compounds.

Lecithin a phospholipid-rich compound (often derived from soy or sunflower), can enhance the bioavailability of certain lipophilic (fat-soluble) and amphipathic compounds by improving their solubility, absorption, and cellular uptake.

Supplements and Compounds with Improved Bioavailability via Lecithin
Curcumin Up to 20–30x better absorption in some formulations
Quercetin
Resveratrol
Silybin (from milk thistle)
Green tea catechins, EGCG Lecithin helps stabilize and protect catechins during digestion
Boswellic acids
Coenzyme Q10 (CoQ10)
Omega-3 fatty acids
Vitamin D, E, A, K (Fat-soluble vitamins)
Alpha-lipoic acid (ALA)
black seed oil (Nigella sativa) and its key active compound, thymoquinone.

Lecithin and Phospholipid Bioavailability Enhancement

Product / Compound	Lecithin / Phospholipid System	Evidence	Relative Effect	Main Improvement	Evidence Strength	Notes / Interpretation
Curcumin / Curcuminoids	Lecithin phospholipid complex / Phytosome	Human randomized crossover PK	↑ ~29-fold total curcuminoid absorption	↑ systemic exposure	High	One of the strongest human examples. The effect applies to the engineered phospholipid formulation rather than simple co-consumption with lecithin.
Curcumin / Curcuminoids	Lecithin-based nanoemulsion	Rat pharmacokinetics	↑ ~5.3-fold total oral bioavailability	↑ Cmax and AUC	Moderate	Total curcuminoid bioavailability was approximately 46% from nanoemulsion versus 8.7% from dispersion.
Curcumin	Soy lecithin oil-in-water emulsion	In-vitro digestion	↑ ~4.8–10.6-fold bioaccessibility; ↑ ~1700-fold apparent water solubility	↑ dispersion and micellarization	Moderate	Strong demonstration of the oil-in-water mechanism, but bioaccessibility should not be equated directly with human systemic bioavailability.
Quercetin	Food-grade lecithin Phytosome	Human randomized crossover PK	↑ up to ~20-fold plasma exposure	↑ Cmax and AUC	High	Strong human evidence. A recent systematic review estimated approximately 20.1-fold higher bioavailability for lecithin phytosome versus quercetin aglycone.
Berberine	Phospholipid / lecithin Phytosome	Human pharmacokinetics	↑ ~10-fold AUC	↑ systemic exposure	High	Particularly relevant because ordinary berberine has very poor oral bioavailability.
Berberine	Berberine-phospholipid complex phytosome	Animal pharmacokinetics	↑ ~3-fold oral bioavailability	↑ absorption	Moderate	Supports the human findings, although the formulation and animal model differ.
Silybin / Silymarin	Silybin-phosphatidylcholine complex	Human pharmacokinetics	↑ marked; substantially higher plasma levels than conventional silymarin	↑ intestinal absorption and systemic exposure	High	Silybin-phosphatidylcholine is one of the classic examples of phospholipid-enhanced phytochemical absorption.
Silybin	Phosphatidylcholine complex in oily softgel	Human crossover PK	↑ Cmax >3-fold; ↑ AUC >2-fold versus another phospholipid formulation	↑ systemic exposure	High	Shows that the surrounding oil and dosage form can further enhance a phospholipid complex.
Silybin	Phospholipid complex plus self-nanoemulsifying system	Rat pharmacokinetics	↑ ~12.7-fold for phospholipid complex; ↑ ~18-fold with phospholipid complex plus SNEDDS	↑ absorption and lymphatic transport	Moderate	Shows potential synergy between phosphatidylcholine complexation and self-emulsification.
Carnosic Acid	Lecithin-based nanoemulsion	Rat PK plus two in-vitro digestion models	↑ ~2.2-fold systemic bioavailability; ↑ ~5.6–12.6-fold bioaccessibility	↑ solubilization and absorption	Moderate	Strong direct evidence specifically using a lecithin nanoemulsion.
Coenzyme Q10	Salmon lecithin and salmon-oil nanoemulsion	Rat pharmacokinetics	↑ ~2-fold bioavailability	↑ absorption of highly lipophilic CoQ10	Moderate	CoQ10 is an especially logical candidate for lecithin-oil delivery because of its extreme hydrophobicity.
Coenzyme Q10	Oil + lecithin + surfactant formulation	Human crossover PK	↑ formulation-dependent	↑ systemic exposure	Moderate	Human studies confirm that emulsification and solubilization materially affect CoQ10 absorption, although lecithin is only one component of these systems.
Resveratrol	Phospholipid complex	Animal pharmacokinetics	↑ systemic exposure; combination phospholipid formulation reported ↑ ~2.5-fold AUC	↑ solubility and absorption	Moderate	The ~2.5-fold formulation also contained glycyrrhetinic acid to inhibit glucuronidation, so the entire increase cannot be assigned to phospholipid alone.
Puerarin	Puerarin-phospholipid complex	Rat pharmacokinetics	↑ ~1.46-fold AUC	↑ absorption	Moderate	AUC increased from approximately 5.78 to 8.46 mg·h/L.
Puerarin	Phospholipid complex microemulsion	Rat pharmacokinetics	↑ ~3.16-fold oral bioavailability	↑ Cmax and AUC	Moderate	Combining phospholipid complexation with microemulsification produced substantially greater enhancement than phospholipid complex alone.
Baicalein	Phospholipid complex matrix dispersion	Rat pharmacokinetics	↑ ~5.0-fold AUC versus free baicalein	↑ dissolution, permeability and systemic exposure	Moderate	The matrix dispersion also contained PVP, so the increase represents the complete phospholipid formulation rather than phospholipid alone.
Baicalin	Soy phospholipid complex	Rat pharmacokinetics	↑ Cmax ~2.1-fold; ↑ AUC significantly	↑ absorption	Moderate	Early direct evidence that soy phospholipid complexation improves baicalin exposure.
Baicalin	Phospholipid complex plus SMEDDS	Rat pharmacokinetics	↑ ~2.20-fold relative bioavailability	↑ intestinal absorption	Moderate	Phospholipid complex alone was not optimal; combination with a self-emulsifying system produced the major improvement.
Apigenin	Phospholipid phytosome	Rat pharmacokinetics	↑ significant oral bioavailability; ↑ >36-fold aqueous solubility	↑ solubility, dissolution and absorption	Moderate	Useful candidate for phospholipid formulation, but a precise systemic fold increase was not reported in the abstract.
Rutin	Egg phosphatidylcholine nano-complex	Rat pharmacokinetics	↑ oral bioavailability	↑ solubility and absorption	Moderate	Phospholipid complexation also increased rutin aqueous solubility substantially.
Rutin	Phospholipid complex	In-vitro formulation	↑ aqueous solubility ~15.9-fold	↑ dissolution	Low to Moderate	Aqueous solubility increased from approximately 2.88 to 45.71 µg/mL; systemic exposure was not established by this study.
Green Tea Catechins / EGCG	Phospholipid complex / Phytosome	Human pharmacokinetics	↑ catechin absorption	↑ plasma EGCG exposure	Moderate to High	Human studies show faster and greater catechin absorption from phospholipid-complexed green tea than from uncomplexed extract.
Beta-Carotene	Lecithin-containing oil-in-water emulsion	In-vitro digestion / cellular uptake	↑ bioaccessibility; magnitude strongly formulation-dependent	↑ micellarization	Moderate	Carrier-oil composition and droplet size can have effects as large as or larger than lecithin itself.
Carotenoids	Lecithin-containing emulsion	In-vitro digestion	↑ ~2-fold at an optimized low lecithin dose	↑ bioaccessibility	Moderate	Higher lecithin concentrations were not necessarily better and could promote droplet aggregation.
Lutein	Lecithin-containing protein emulsion	In-vitro digestion	↑ ~13.5% bioaccessibility	↑ micellarization	Moderate	Lecithin can improve lutein delivery, although other emulsifiers and proteins can substantially influence the result.
Lutein	Soy lecithin complex in grape-seed-oil emulsion	In-vitro digestion	↑ bioavailability to ~25–28% of loaded lutein	↑ stability and gastrointestinal delivery	Moderate	Illustrates the use of lecithin combined with a digestible vegetable oil to improve delivery.
Lycopene	Lecithin-containing micelle / chylomicron system	Rat pharmacokinetics	↑ oral bioavailability to ~6.8–9.5%	↑ absorption	Moderate	The chylomicron-like system produced greater bioavailability than the smaller micellar system despite larger particle size.
Lycopene	Lecithin-containing microemulsion	Rat pharmacokinetics	↑ ~2.1-fold relative bioavailability	↑ absorption and tissue delivery	Moderate	The formulation also increased relative delivery to brain tissue in animal experiments.
Astaxanthin	Modified lecithin oil-in-water nanoemulsion	In-vitro digestion / formulation	↑ bioaccessibility	↑ stability and gastrointestinal dispersion	Low to Moderate	Evidence supports improved delivery, but robust human comparative pharmacokinetic data are lacking.
Vitamin E	Lecithin-containing protein emulsion	In-vitro digestion	↑ ~187% bioaccessibility	↑ micellarization	Moderate	One of the larger increases reported in an emulsion digestion model; this represents bioaccessibility rather than human systemic bioavailability.
DHA	Soy-lecithin oil-in-water emulsion	In-vitro digestion	↑ bioaccessibility versus bulk algal oil	↑ early lipolysis and micellar transfer	Moderate	Benefit depended on the emulsion remaining sufficiently intact through the gastric stage.
DHA	Lecithin-containing protein emulsion	In-vitro digestion	↑ ~36% bioaccessibility	↑ lipid digestion and micellarization	Moderate	Supports lecithin as a useful emulsifier for omega-3 lipid delivery.
EPA + DHA	Lecithin self-emulsifying delivery system	Rat pharmacokinetics	↑ Cmax ~1.38–1.40-fold; ↑ AUC ~1.27–1.29-fold	↑ gastrointestinal absorption	Moderate	Direct evidence that lecithin-containing self-emulsifying systems can enhance omega-3 absorption.
General Lipophilic Oils / Extracts	Lecithin oil-in-water emulsion	Mechanistic / formulation evidence	↑ variable	↑ dispersion, digestive surface area and mixed-micelle formation	High mechanistic plausibility	Most promising for hydrophobic compounds with poor aqueous solubility. Benefit depends strongly on the carrier oil, droplet size, phospholipid concentration and digestive stability.

Interpretation: The strongest human evidence for large lecithin/phosphatidylcholine-associated increases in oral exposure currently exists for curcuminoids, quercetin, berberine and silybin. Animal evidence also supports carnosic acid, CoQ10, resveratrol, puerarin, baicalein, baicalin and several other poorly soluble phytochemicals. Carotenoids, vitamin E, DHA and other lipid-soluble nutrients show strong formulation and gastrointestinal bioaccessibility effects, although the magnitude of systemic enhancement is less consistently established in humans.

Important formulation constraint: The values above describe specific engineered phospholipid complexes, phytosomes, nanoemulsions, liposomes or self-emulsifying systems. They should not be interpreted as expected fold increases from simply taking a lecithin capsule with the listed product. For practical oral bioenhancement, lecithin generally performs best when the active compound is dissolved or dispersed with a suitable digestible oil and processed into a stable fine oil-in-water emulsion or phospholipid complex.

Lecithin Bioavailability Mechanisms

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Oil-in-water emulsification	↔	↔	P/R	↑ aqueous dispersion of lipophilic compounds	Lecithin is amphiphilic and accumulates at oil-water interfaces, enabling stable or semi-stable dispersions of hydrophobic compounds in aqueous systems.
2	Gastrointestinal micellarization	↔	↑ intestinal bioaccessibility	R	↑ solubilization into absorbable mixed micelles	Lipid digestion products, bile salts, phospholipids, and lecithin-derived components participate in colloidal structures capable of carrying lipophilic compounds through the intestinal aqueous phase.
3	Phospholipid complex formation	↑ drug delivery (formulation-dependent)	↑ absorption (formulation-dependent)	R/G	↑ solubility and membrane-compatible delivery	Phytosome-type systems associate bioactive molecules with phosphatidylcholine-rich lecithin and can substantially increase oral exposure.
4	Nanoemulsion delivery	↑ drug exposure (formulation-dependent)	↑ absorption (formulation-dependent)	R/G	↑ surface area and gastrointestinal dispersion	Reducing lipid droplets to nano-scale dimensions can increase contact with digestive enzymes and facilitate transfer of encapsulated lipophilic compounds into mixed micelles.
5	Liposomal encapsulation	↑ delivery of co-formulated agent	↑ delivery of co-formulated agent	R/G	Encapsulation and controlled delivery	Phospholipid bilayers can encapsulate lipophilic or amphiphilic compounds and modify stability, release, and tissue exposure.
6	Compound stability	↑ effective exposure	↑ effective exposure	R/G	↓ degradation	Lecithin emulsions may protect susceptible compounds from light, heat, oxidation, or precipitation, increasing the amount remaining available for absorption.
7	Systemic bioavailability	↑ exposure to co-formulated agent	↑ exposure to co-formulated agent	G	↑ Cmax and AUC	Human and animal studies demonstrate substantial but highly formulation-specific increases in systemic exposure for selected poorly soluble compounds.
8	Clinical Translation Constraint	↔	↔	G	Formulation dependence	Enhancement depends on lecithin dose and composition, oil phase, particle size, manufacturing process, digestive stability, and the physicochemical properties of the active compound. Ordinary lecithin co-consumption cannot be assumed to reproduce engineered formulation results.

TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr

Alzheimer's disease relevance: Lecithin and phosphatidylcholine have longstanding mechanistic interest in Alzheimer's disease because they provide choline for acetylcholine synthesis and phospholipids for neuronal membranes. Cholinergic dysfunction is an important feature of AD, and oral phosphatidylcholine can increase circulating choline. Preclinical and observational evidence also supports possible effects on membrane integrity, synaptic function and one-carbon metabolism. However, randomized clinical studies of lecithin in established dementia have not shown a clear cognitive or functional benefit. Lecithin should therefore be classified as mechanistically plausible but clinically unproven for AD rather than as an established neuroprotective treatment.

ROS, Reactive Oxygen Species: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination


Item  ROS↑  NRF2  Condition  Mechanism Class  Remarks  

ROS">Piperlongumine
+++  ↓  [D][T]  ROS-dominant
Selective <span class="wphighlight">ROS</span> stressor, Prevents compensatory upregulation of NRF2, ie GSH↓



ROS">Shikonin
+++ ↓/± [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + glycolysis + GPX4 inhibition



ROS">Vitamin K3 (menadione)
+++ ↓ [D] ROS-dominant
Quinone redox cycler; toxicity limits use



ROS">Copper (ionic / nano)
+++ ↓ [Fe][F] ROS-dominant
Fenton-type redox chemistry



ROS">Sodium Selenite
+++ ↓ [D] ROS-dominant
Pro-oxidant, depletes GSH



ROS">Juglone
+++ ↓ [D] ROS-dominant
Strong quinone <span class="wphighlight">ROS</span> chemistry



ROS">Auranofin
+++ ↓ [D] ROS-dominant
TrxR inhibition → redox collapse



ROS">Photodynamic Therapy (PDT)
+++ 0 [L][O₂] ROS-dominant
Singlet oxygen is core cytotoxic mechanism



ROS">Radiotherapy / Radiation
+++ 0 [O₂] ROS-dominant
DNA damage largely via <span class="wphighlight">ROS</span>



ROS">Doxorubicin
+++ ↓ [D] ROS-dominant
Chemo; redox cycling + mitochondrial <span class="wphighlight">ROS</span>



ROS">Cisplatin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> contributes to DNA/protein damage



ROS">Salinomycin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated CSC toxicity



ROS">Artemisinin / DHA
++ ↓ [Fe][T] ROS-dominant
Iron-activated radical generation



ROS">Sulfasalazine
++ ↓ [C][T] ROS-dominant
Ferroptosis; xCT inhibition → lipid <span class="wphighlight">ROS</span>



ROS">FMD / fasting
++ ↓ [M][C][O₂] ROS-dominant
Metabolic stress → mitochondrial <span class="wphighlight">ROS</span>



ROS">Vitamin C (pharmacologic)
++ ↓ [Fe][D] ROS-dominant
Extracellular H₂O₂ at high dose



ROS">Silver nanoparticles
++ ± [F][D] ROS-dominant
<span class="wphighlight">ROS</span> common; selectivity unreliable



ROS">Gambogic acid
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Parthenolide
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + NF-κB suppression



ROS">Plumbagin
++ ↓ [D] ROS-dominant
Quinone <span class="wphighlight">ROS</span> driver



ROS">Allicin
++ ↓ [D] ROS-dominant
Thiol-reactive oxidative stress



ROS">Ashwagandha (Withaferin A)
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Berberine
++ ↓ [D][M] ROS-dominant
Mitochondrial <span class="wphighlight">ROS</span> induction



ROS">PEITC
++ ↓ [D][C] ROS-dominant
GSH depletion + <span class="wphighlight">ROS</span>



ROS">Methionine restriction
+ ↓ [M][C][T] ROS-secondary
Redox vulnerability increased; <span class="wphighlight">ROS</span> indirect



ROS">DCA
+ ± [M][T] ROS-secondary
<span class="wphighlight">ROS</span> via forced OXPHOS



ROS">Capsaicin
+ ± [D][T] ROS-secondary
Ca²⁺ stress → <span class="wphighlight">ROS</span>



ROS">Galloflavin
+ 0 [D] ROS-secondary
<span class="wphighlight">ROS</span> not primary driver



ROS">Piperine
+ ± [D][F] ROS-secondary
Weak <span class="wphighlight">ROS</span> induction



ROS">Propyl gallate
+ ↓ [D] ROS-secondary
Pro-oxidant at high dose



ROS">Scoulerine
+ ? [D][T] ROS-secondary
Sparse <span class="wphighlight">ROS</span> data



ROS">Thymoquinone
± ± [D][T] Dual redox
Antioxidant ↔ pro-oxidant switch



ROS">Emodin
± ± [D][T] Dual redox
Not cancer-exclusive



ROS">Alpha-lipoic acid (ALA)
± ↑ [D][M] NRF2-dominant
Antioxidant at low dose



ROS">Curcumin
± ↑/↓ [D][F] NRF2-dominant
Hormetic redox behavior



ROS">EGCG
± ↑/↓ [D][O₂] NRF2-dominant
Auto-oxidation artifacts common



ROS">Quercetin
± ↑/↓ [D][Fe] NRF2-dominant
GSH-dependent cycling



ROS">Resveratrol
± ↑ [D][M] NRF2-dominant
<span class="wphighlight">ROS</span> only at high dose



ROS">Sulforaphane
± ↑↑ [D] NRF2-dominant
Strong NRF2 activator



ROS">Lycopene
0 ↑ — Antioxidant
Consistently antioxidant



ROS">Rosmarinic acid
0 ↑ — Antioxidant
Primarily antioxidant



ROS">Citrate
0 0 — Neutral
Metabolic; not a <span class="wphighlight">ROS</span> agent

Scientific Papers found: Click to Expand⟱

8182-

BSO,

LEC,

The Protecting Role of Black Seed Oil and Its Nano-Formulation in LPS-Induced Acute Kidney Injury in Mice: Evaluation of Oxidative Stress, Biochemical & Molecular Parameters

in-vivo,

Nor,

Forty-eight mice

*Inflam↓, *ROS↓, *RenoP↑, *Dose↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Total Targets: 0

Pathway results for Effect on Normal Cells:

Functional Outcomes(tgid=23) ⓘ

RenoP↑, 1,
Total Targets: 4

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:114  Target#:275  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

Lecithin / ROS Cancer Research Results

Lecithin and Phospholipid Bioavailability Enhancement

Lecithin Bioavailability Mechanisms

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Functional Outcomes(tgid=23) ⓘ

Home Page